Radcliffe Cardiology’s Post

Just published in the European Heart Journal Acute Cardiovascular Care (https://lnkd.in/gDeAWtYD): Prehospital Tirofiban Increases the Rate of Disrupted Myocardial Infarction in Patients with ST-Segment Elevation Myocardial Infarction: Insights From the On-TIME 2 Trial by Sem Rikken,  Enrico Fabris, Tobias Rosenqvist, Evangelos Giannitsis,  Jur ten Berg, Christian Hamm, Arnoud van 't Hof. Among STEMI patients undergoing primary PCI, the use of prehospital tirofiban was independently associated with a higher rate of disrupted MI. These results, highlighting a potential benefit, underscore the need for future research focusing on innovative pretreatment approaches which may increase the rate of disrupted MI such as #zalunfiban being studied in the #CeleBrate Trial. #STEMI, #prehospital #CeleBrateTrial #Cardiology #clinicaltrials #cardiovascular #PrehospitalCare #HealthcareProfessionals #HeartHealth #clinicalresearch

The #ESC2024 guidelines are redefining how we approach Chronic Coronary Syndromes with new insights into the use of CCTA and FFRCT. In this short video, Jonathon Leipsic and Gianluca Pontone, MD, PhD break down the key updates and discuss their implications for clinical practice. With #FFRCT now included with a Class I recommendation for higher-risk patients, the guidelines signal a growing focus on non-invasive diagnostics. This is a pivotal moment for cardiovascular care, with CCTA and FFRCT leading the way toward more accurate diagnostics and better outcomes. Don’t miss this opportunity to learn how these changes could enhance your approach to patient care! Watch the video and learn more about HeartFlow: https://ow.ly/HFOb50TOb4x #ESC2024 #CAD #CCTA

NEW Interview 🎙️ Dr Joanna Wykrzykowska, Prof Holger Thiele and Prof Prof. Dr. Helge Möllmann discuss the findings and clinical implications of the PROVE Registry! https://ow.ly/GXPZ50SFQFy Watch now to uncover: 📊 Design and goal of the study ✅ Endpoints and results 📚 Implications on clinical practice #Cardiology #PROVE

We're delighted to have Sem Rikken present "TCT 329: Pharmacokinetics of 14C-Labeled Zalunfiban (RUC-4) Suggests That No Dose Adjustment Is Necessary for Impaired Renal Function". 📅 Date: Wednesday, October 30, 2024 ⏰ Time: 8:45 AM 📍 Session: CKD, AKI, and Contrast Management-2 | TCT2024 This presentation will be on behalf of Robert B. MacArthur, PharmD, MS, BCSCP, Barry Coller, C. Michael Gibson, M.S., M.D., Chris Granger, Gilles Montalescot, Jur ten Berg, and Arnoud van 't Hof. 💡 Exciting new data emerging about #zalufiban and its potential role in treating patients with heart attacks. #TCT2024 #hearthealth #cardiology #pharmacokinetics

🎉 It’s here! Our Patient-Focused Guide to Breast Screening is Now Live! 🎉 We’re excited to announce that our Patient-Focused Guide to Attending a Breast Screening Appointment is now available! 💖 Whether you're attending your first breast screening appointment or simply want to know more about the process, this guide provides information for patients to feel prepared. 📖 What’s inside? • What to expect during a screening • Tips on preparing for your appointment • Answers to common patient concerns Read our guide here: https://lnkd.in/e572U3TE #PatientEducation #BreastScreening #BreastCancerAwareness #EarlyDetection #PatientEmpowerment #InterventionalRadiology #ItsInterventional

A new therapy on the horizon for microvascular patients? Join Dr. Francesco Giannini tomorrow morning as he presents the first-in-man experience of the A-FLUX Coronary Sinus Reducer. This session will review how the first patients, including coronary microvascular patients, were treated with A-FLUX therapy and how it impacted their symptoms. Come and see! 🗓️October 30, 2024, 9:24 AM – 9:29 AM 📍 Walter E. Washington Convention Center | Moderated Abstracts Station 6 #TCT2024 #Cardiology #CMD #AFLUXReducer #VahatiCor #coronary #coronarymicrovasculardysfunction #microvascular #coronarysinusreducer #interventionalcardiology

The effectiveness and safety of sacubitril/valsartan in hospitalized heart failure patients across varying left ventricular ejection fraction levels remain unexplored. Data from the PIONEER-HF and PARAGLIDE-HF trials was pooled, examining treatment outcomes across the EF spectrum (≤40% and >40%) following recent worsening heart failure (WHF). This recently published analysis aims to shed light on sacubitril/valsartan's efficacy, offering valuable insights for managing acute HF episodes. Authors concluded that following stabilization after a recent episode of WHF, patients treated with sacubitril/valsartan experienced significantly greater reductions in plasma NT-proBNP levels and demonstrated improved clinical outcomes compared to those receiving control therapy. This effect was particularly notable across the spectrum of left ventricular ejection fraction ≤60%. These findings were observed in the PIONEER-HF and PARAGLIDE-HF Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation. For details 👇 https://lnkd.in/e99MnE6a #agposts #cardiacupdate #HeartFailure #clinicaltrials #ClinicalResearch #cardiology #cardiologists

In case you missed it back in May, we wanted to reshare the highlights from our multi-specialist panel discussion featuring Dan Lister, MD FACS FAFS, Dr. Farhan Q., and Sarah Enslin, PA-C. You can watch the full-length session here: https://hubs.la/Q02G9zyF0 Highlights: 💬 Lister: "Before TissueCypher, the problem that we had was that an endoscopic biopsy provided a static picture of a dynamic situation... TissueCypher allows us to have a video so we know what patients [are going to progress]." 💬 Enslin: "That's the other unmet need-- how can we provide information to patients in ways that they can understand it, and how do we translate that into a conversation with them?" 💬 Quader: What I normally say [to patients] is that these are all pieces of a puzzle. And we're using all of these small pieces to figure out what I should do for you specifically and not for someone else.

Better longterm (5 year) patient outcomes reveal the true clinical power of hsTn. It’s not only about infarct, this High-STEACS secondary analysis shows that identifying non-ischemic myocardial injury can help patients with pathology which needs something other than an urgent cardiac cath. The more early myocardial injury that can be identified, the more value-based outcomes patients can receive from hsTn.